Effect of rosuvastatin on cardiac structural indexes and kidney function in patients with essential hypertension

November 14, 2016
851
Resume

In a study, which included 40 patients with essential hypertension, it was shown an improvement of the left ventricular structural indexes and kidney function by adding of rosuvastatin to a fixed dose combination of valsartan and amlodipine. It is confirmed by a greater reduction of the left ventricular mass index, an increase in glomerular filtration rate and reduction of the urinary albumin excretion while taking rosuvastatin in comparison with the control group.

Published: 15.11.2016

References:

  • Mishchenko L.A. (2012) Predyktory prohresuvannia hipertrofii livoho shlunochka u khvorykh na hipertonichnu khvorobu. Ukr. kardiol. zhurn., 6: 110–116.
  • Mishchenko L.A. (2015) Predyktory pohirshennia funktsionalnoho stanu nyrok u khvorykh na hipertonichnu khvorobu. Ukr. kardiol. zhurn., 4: 47–52.
  • Burridge K., Wennerberg K. (2004) Rho and Rac take center stage. Cell, 116(2): 167–179.
  • Cuspidi C., Facchetti R., Bombelli M. et al. (2013) Nighttime blood pressure and new-onset left ventricular hypertrophy: findings from the Pamela population. Hypertension, 62(1): 78–84.
  • Dolan E., O’Brien E. (2016) Nocturnal blood pressure relates more closely to kidney disease in the Dublin outcome study. J. Hypertens., 34 Suppl. 2, 23 p.
  • Hermida R., Ayala D., Mojon A. et al. (2011) Decreasing sleeptime blood pressure determined by ambulatory monitoring reduces cardiovascular risk. J. Am. Coll. Cardiol., 58: 1165–1167.
  • Kanaki A.I., Sarafidis P.A., Georgianos P.I. et al. (2012) Low-dose atorvastatin reduces ambulatory blood pressure in patients with mild hypertension and hypercholesterolaemia: a double-blind, randomized, placebo-controlled study. J. Hum. Hypertens., 26(10): 577–584.
  • Kudo S., Satoh K., Nogi M. et al. (2016) SmgGDS as a Crucial Mediator of the Inhibitory Effects of Statins on Cardiac Hypertrophy and Fibrosis: Novel Mechanism of the Pleiotropic Effects of Statins. Hypertension, 67(5): 878–889.
  • Levey A.S., Stevens L.A., Schmid C.H. et al., CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) (2009) A new equation to estimate glomerular filtration rate. Ann. Intern. Med., 150(9): 604–612.
  • Ogata N., Fujimori S., Oka Y., Kaneko K. (2010) Effects of three strong statins (atorvastatin, pitavastatin, and rosuvastatin) on serum uric acid levels in dyslipidemic patients. Nucleosides Nucleotides Nucleic. Acids., 29(4–6): 321–324.
  • Pena M., Lopez J.E., Hermida A. (2010) Effects of rosuvastatin on blood pressure in hypertensive subjects with dyslipidemia. J. Hypertens., 28, (Suppl. A) 145 p.
  • Poulikakos D., Ross L., Recio-Mayoral A. et al. (2014) Left ventricular hypertrophy and endothelial dysfunction in chronic kidney disease. Eur. Heart J. Cardiovasc. Imaging., 15(1): 56–61.
  • Ridker P.M., Danielson E., Fonseca F.A. et al., JUPITER Study Group (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med., 359(21): 2195–2207.
  • Sano M., Fukuda K., Kodama H. et al. (2000) Interleukin-6 family of cytokines mediate angiotensin II-induced cardiac hypertrophy in rodent cardiomyocytes. J. Biol. Chem., 275(38): 29717–29723.
  • Savarese G., Musella F., Volpe M. et al. (2013) Effects of atorvastatin and rosuvastatin on renal function: a meta-analysis. Int. J. Cardiol., 167(6): 2482–2489.
  • Sever P.S., Dahlöf B., Poulter N.R. et al.; ASCOT investigators (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial — Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet, 361(9364): 1149–1158.
  • Wang G., Hamid T., Keith R.J. et al. (2010) Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart. Circulation, 121(17): 1912–1925.
  • Yusuf S., Bosch J., Dagenais G. et al., HOPE-3 Investigators (2016) Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N. Engl. J. Med., 374(21): 2021–2031.
  • Zhou Q., Liao J.K. (2010) Pleiotropic effects of statins. Basic research and clinical perspectives. Circ. J., 74(5): 818–826.